Cost-utility analysis of difelikefalin for the treatment of moderate to severe Chronic Kidney Disease associated-Pruritus (CKD-aP) in adult patients receiving haemodialysis in Spain.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Sánchez-Alvarez E
  • Sánchez-Villanueva R
  • De La Paz Cañizares I
  • Ramirez de Arellano A
  • Ruiz-Andrés O

Grupos

Abstract

BACKGROUND AND OBJECTIVES: Chronic Kidney Disease-associated Pruritus (CKD-aP) is a disabling condition that affects around 60% of patients with end-stage kidney disease undergoing dialysis. Current off-label treatment options are neither effective nor appropriate for all dialysis patients, leaving a clear unmet need. This study aimed to evaluate the cost-effectiveness of difelikefalin - the only drug approved in Europe for the treatment of moderate to severe CKD-aP adult patients in haemodialysis - compared to the best supportive care (BSC) from the Spanish NHS perspective. METHODS: A Markov model was developed with seven health states: five health states representing levels of pruritus intensity over time (No, Mild, Moderate, Severe and Very severe CKD-aP), kidney transplant and death as the absorbing state. The model included patients with moderate to severe CKD-aP at baseline, in line with difelikefalin approved indication and clinical trials. Local costs, utilities, mortality rates and kidney transplant probabilities were obtained from published literature. Costs and quality-adjusted life-years (QALYs) were discounted at a 3% annual rate with a lifetime horizon (36 years). RESULTS: Difelikefalin was associated with an increased in QALYs (+0.49) and higher costs (+12,300€) compared to the BSC over a lifetime horizon. At a provisional cost estimate of 270.6€per 28-days for difelikefalin (based on a tentative list price for Spain), the incremental cost-utility ratio was 25,000€/QALY. The sensitivity analysis (DSA) confirmed the robustness of the results. The probabilistic sensitivity analysis (PSA), undertaken with 1000 iterations, indicated a 50% and 83% probability of difelikefalin being cost-effective at a willingness-to-pay (WTP) thresholds of 25,000 €/QALY and 30,000 €/QALY, respectively. CONCLUSIONS: Difelikefalin could be a cost-effective option compared to BSC for the management of CKD-aP in adult haemodialysis patients within the Spanish NHS setting. Considering the unmet needs, these results support the convenience of incorporating difelikefalin in routine clinical practice in Spain.

Datos de la publicación

ISSN/ISSNe:
1369-6998, 1941-837X

JOURNAL OF MEDICAL ECONOMICS  TAYLOR & FRANCIS LTD

Tipo:
Article
Páginas:
835-847
PubMed:
40411773
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,641 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • D61; I00; I11; I18; Kidney diseases; chronic pruritus; cost-utility analysis; kidney dialysis; quality-adjusted life years

Cita

Compartir